ArticleJournal of clinical laboratory analysis2025
Integrated Transcriptomic and Metabolomic Analysis Revealed That Tryptophan Metabolism-Related Metabolites Are Biomarkers of Trastuzumab Resistance.
Article in Journal of clinical laboratory analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Investigation of potential sex-based differences in trastuzumab-induced chronic cardiotoxicity in a rat model.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTrastuzumab resistance strongly affects the prognosis of HER2-positive breast cancer patients, and tryptophan metabolism plays a key role in cancer progression and cancer prognosis. However, the relationship between trastuzumab resistance and tryptophan metabolism in HER2-positive breast cancer remains unclear.
methodsFour HER2-positive breast cancer cell lines (TS: BT-474, SK-BR-3; TR: HCC1954, JIMT-1) were cultured in specific media. Metabolites from cells, tissues, and serum were extracted via pretreatment, centrifugation, drying, and redissolution. UPLC-MS/MS was used for metabolite detection, while tryptophan metabolism-related gene expression was measured using qRT-PCR. T-test was used to calculate statistical differences. Data visualization, machine learning models construction (RF, LASSO logistic regression), and nomogram were achieved through R language.
resultsPLS-DA showed distinct separation between TS and TR breast cancer cell lines in tryptophan metabolism-related gene expression (four differentially expressed genes: HAAO, KYNU, KMO, AFMID) and metabolite abundance (five differentially abundant metabolites). Integration analysis identified 3-hydroxyanthranilic acid, cinnabarinic acid, kynurenine, and kynurenic acid as potential metabolic biomarkers. These four metabolites differed significantly in serum of HCs, TS and TR patients. Four predictors were selected by LASSO, and a nomogram was constructed based on logistic regression. Finally, biomarkers and related genes were validated in tissues.
conclusionOur explored the changes induced by trastuzumab resistance in terms of metabolite abundance and gene transcription levels associated with tryptophan metabolism. Furthermore, this work provided new insights into novel diagnostic biomarkers and prediction models of trastuzumab resistance in HER2-positive breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.